ERBB2 and cancer: Indeed, other retrospective evaluations highlighted the poor prognosis in some subsets of small cancers: a series from the MD Anderson Cancer Center, including 965 patients with small node-negative breast cancers not receiving adjuvant chemotherapy or trastuzumab, showed a higher risk of recurrence in Her-2 positive and TN subsets (Gonzalez-Angulo et al. 2009).